Table 1.

Primary CD8⁺ T cell activation markers and checkpoint inhibitors 48 hours after exposure to SKOV3 tumor cells and various IgGs and IgG BsAbs (10:1 E:T). Results were similar for CD4⁺ T cell activation markers and checkpoint inhibitors

Test article	CD69 (%+)	CD25 (%+)	PD-1 (%+)	4-1BB (%+)	CTLA-4 (%+)
IgG1 control 0.1 nM	2.7	0	1	0.2	0
IgG1 control 0.01 nM	2.3	0.1	0.8	0.1	0
IgG1 control 0.001 nM	2.1	0.6	1.2	0	0
SP34 IgG1_N297Q 0.1 nM	32.7	2.4	1.7	2.2	0
SP34 IgG1_N297Q 0.01 nM	5.8	0.1	1.7	0.2	0
SP34 IgG1_N297Q 0.001 nM	1.8	0	1.4	0	0
Pertuzumab IgG1 0.1 nM	1.5	0	1	0	0
Pertuzumab IgG1 0.01 nM	2.1	0.1	1.1	0	0
Pertuzumab IgG1 0.001 nM	2.5	0.2	1.3	0	0
SP34+Pertuz IgGs 0.1 nM	26.1	1.4	1.8	3.7	0
SP34+Pertuz IgGs 0.01 nM	4.3	0.2	1.3	0.1	0.1
SP34+Pertuz IgGs 0.001 nM	1.7	0.1	1	0	0.1
SP34/Pertuz IgG BsAb 0.1 nM	96.7	85.7	75.7	85.3	9.5
SP34/Pertuz IgG BsAb 0.01 nM	84.7	65.5	51.7	79.7	3.5
SP34/Pertuz IgG BsAb 0.001 nM	44.4	16.1	11.2	19.7	0.4
SP34_F100fH/Pertuz IgG BsAb 0.1 nM	87.5	73.8	56	80.9	2.3
SP34_F100fH/Pertuz IgG BsAb 0.01 nM	46.6	18.1	10.4	15.7	0.2
SP34_F100fH/Pertuz IgG BsAb 0.001 nM	3	0	0.9	0.2	0.1

BsAb, bispecific antibody; PD-1, Programmed cell death 1.